Study of Induction Chemoimmunotherapy Followed by Chemoradiotherapy and Consolidation Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer
Led by Shanghai Chest Hospital · Updated on 2026-07-23
108
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new treatment approach for patients with unresectable locally advanced non-small cell lung cancer NSCLC. The study is a multicenter phase III trial designed to assess induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy. The purpose is to improve progression-free survival compared to the current standard PACIFIC regimen while maintaining safety.
The study has two parts phase I is a single-arm safety lead-in assessing the investigational regimens safety and initial efficacy. If safe, phase II is a randomized trial comparing the investigational treatment against the standard PACIFIC regimen. Induction treatment includes 2 to 4 cycles of platinum-based chemotherapy combined with a PD-L1 inhibitor, followed by concurrent chemoradiotherapy and then consolidation immunotherapy with a PD-L1 inhibitor for up to one year or until disease progression or unacceptable toxicity.
Participants undergo assessments for treatment response, safety, and survival outcomes, including progression-free survival and overall survival. Safety is monitored through adverse event tracking, and exploratory analyses evaluate minimal residual disease as a potential marker of treatment response. The total study duration includes treatment periods and follow-up for up to 60 months to assess long-term outcomes.
CONDITIONS
Brief Title
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
Research Team
W
Wen Yu, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Age over 18 years with ECOG performance status 0-1
Histologically or cytologically confirmed non-small cell lung cancer
Unresectable stage III NSCLC as per AJCC 8th edition
No prior anti-tumor therapy
Adequate blood, liver, kidney, heart, and lung function meeting specific laboratory criteria
Life expectancy of at least 3 months
Ability to understand the study, complete treatment, follow-up, and provide informed consent
You will not qualify if you...
Presence of small cell carcinoma components
Positive for EGFR mutation, ALK rearrangement, or ROS-1 rearrangement
History of other primary malignancies except for certain treated cancers with no active disease for 5 years
Active or past autoimmune or inflammatory diseases
History of allogeneic organ transplantation
History of active primary immunodeficiency
Uncontrolled illnesses including infections, heart conditions, severe gastrointestinal disease, or psychiatric/social issues limiting compliance
Pregnant or breastfeeding women
Use of immunosuppressive medication within 14 days before treatment except certain corticosteroids
Known allergy to study drugs or their excipients
Inability to comply with study procedures or provide consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Phase I Safety Lead-in
Duration - Approximately 2 to 4 months
Participants receive 2 to 4 cycles of induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy to evaluate safety and preliminary efficacy.
Multiple visits during treatment cycles
Phase II Randomized Treatment
Duration - Up to 12 months of consolidation immunotherapy plus preceding treatments
Participants are randomly assigned to receive either induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy or the standard PACIFIC regimen. Treatment lasts up to one year or until disease progression or unacceptable toxicity.
Regular visits during chemotherapy, radiotherapy, and immunotherapy phases
Follow-up
Duration - Up to 60 months
Participants are monitored for progression-free survival, overall survival, and treatment-related adverse events for up to 60 months after treatment initiation.
Periodic follow-up visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Using 3-D Virtual Lung Resection to Predict Lung Function After VATS Surgery for Non-Small Cell Lung Cancer
Early Evaluation of Neoadjuvant Immunotherapy Response
Using 68Ga-grazytracer PETCT in Resectable Non-Small Cell Lung Cancer
Patients Aged 18 to 75 Years
Evaluating Calderasib with Subcutaneous Pembrolizumab Versus Pembrolizumab Plus Chemotherapy
for KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer
Randomized Study of Adjuvant Cemiplimab Versus Observation in Patients With Surgically Removed Stage II-IIIA Non-Small Cell Lung Cancer Without Prior Chemotherapy
Evaluating Adjuvant Intismeran With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa Compared to Placebo in High-Risk Stage I Non-Small Cell Lung Cancer
Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in People With Locally Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer After Chemoradiotherapy
Phase 2 Study of TQB2102 Injection for Treating Locally Advanced or Metastatic Non-Small Cell Lung Cancer with HER2 Gene Abnormality
Phase I Study of Intravenous CEA-Targeted CAR-T Therapy for Advanced CEA Positive Solid Tumors
Testing Safety and Effectiveness of BNT326 and Pumitamig Combination Therapy in Advanced Non-small Cell Lung Cancer
Phase IIIb Study to Evaluate the Safety and Effectiveness of Vebreltinib PLB1001 in Adults With Advanced or Metastatic Non-Small Cell Lung Cancer Having MET Exon 14 Mutation
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer.
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.